申请人:Zeria Pharmaceutical Co., Ltd.
公开号:US05409956A1
公开(公告)日:1995-04-25
The present invention relates to indan derivatives represented by the formula (1) or pharmaceutically acceptable salts thereof: ##STR1## [wherein R.sup.1 represents C1 to C12 alkyl, benzyl, styryl, naphthyl, optionally substituted phenyl or optionally substituted thienyl; R.sup.2 represents carboxyl, C1 to C4 alkoxycarbonyl, ##STR2## Y represents --(CH.sub.2).sub.p -- (wherein p represents an integer of 0 to 5), --CO--(CH.sub.2).sub.q .about., --CH(OH)--(CH.sub.2).sub.q .about., (wherein q represents an integer of 1 to 4, and the symbol .about. represents a linkage to R.sup.2), oxymethylene or ethylene; and n represents an integer of 1 to 4]. The compounds according to the present invention potently antagonize the action of thromboxane A.sub.2, and therefore useful for the treatment and prevention of diseases caused by thromboxane A.sub.2 such as angiosis, vasospasm, asthma and the like.
本发明涉及由式(1)表示的吲哚衍生物或其药学上可接受的盐:##STR1## [其中R.sup.1代表C1到C12烷基,苄基,苯乙烯基,萘基,可选择地取代的苯基或可选择地取代的噻吩基;R.sup.2代表羧基,C1到C4烷氧羰基,##STR2## Y代表--(CH.sub.2).sub.p--(其中p代表0到5的整数),--CO--(CH.sub.2).sub.q .about.,--CH(OH)--(CH.sub.2).sub.q .about.,(其中q代表1到4的整数,符号.about.代表与R.sup.2的连接),氧甲亚甲基或乙烯基;n代表1到4的整数]. 根据本发明的化合物强力拮抗血栓素A.sub.2的作用,因此对于治疗和预防由血栓素A.sub.2引起的疾病如血管病,血管痉挛,哮喘等非常有用。